Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.

Abstract

Objective: To determine whether the positivity of baseline anti-Ro/Sjögren's syndrome antigen A (SSA) antibodies influences the response to abatacept, we compared therapeutic responses between anti-Ro/SSA antibody-negative and -positive patients with rheumatoid arthritis (RA) using a multicentre RA ultrasonography prospective cohort. Method: We reviewed Japanese patients with RA who started abatacept as the first biological disease-modifying anti-rheumatic drug between June 2013 and April 2018. We assessed 28-joint Disease Activity Score-erythrocyte sedimentation rate (DAS28-ESR) change between baseline and 6 or 12 months after treatment in RA patients treated with abatacept, and European League Against Rheumatism (EULAR) response at 6 and 12 months. The Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated at baseline and at 6 and 12 months. Results: Overall, 51 patients were enrolled and divided into anti-Ro/SSA antibody-negative and -positive groups of 35 and 16, respectively. Median age at baseline was significantly higher in the anti-Ro/SSA antibody-negative group (p = 0.04). The retention rate and percentage of EULAR good responders at 12 months were significantly higher in the anti-Ro/SSA antibody-negative group (both p = 0.02). Anti-Ro/SSA antibody-negative patients exhibited larger decreases in both DAS28-ESR and DAS28-C-reactive protein at 12 months than anti-Ro/SSA antibody-positive patients (p = 0.02 and 0.04, respectively). GLOESS decreased significantly at 6 months in anti-Ro/SSA antibody-negative patients (p = 0.03). Multivariate analyses showed that anti-Ro/SSA antibody positivity was an independent factor associated with change in the DAS28-ESR at 6 months (p < 0.05). Conclusion: Anti-Ro/SSA antibody positivity predicts a poor response to abatacept and low retention rate.

• Authors: Y Endo, T Koga, S-Y Kawashiri, S Morimoto, A Nishino, M Okamoto, S Tsuji, A Takatani, T Shimizu, R Sumiyoshi, T Igawa, N Iwamoto, K Ichinose, M Tamai, H Nakamura, T Origuchi, Y Ueki, T Yoshitama, N Eiraku, N Matsuoka, A Okada, K Fujikawa, H Hamada, T Tsuru, S Nagano, Y Arinobu, T Hidaka, Y Tada, A Kawakami
• Journal: Scandinavian journal of rheumatology (Scand J Rheumatol) Vol. 50 Issue 1 Pg. 15-19 (Jan 2021) ISSN: 1502-7732 [Electronic] England
• PMID: 32880228 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antirheumatic Agents
• Autoantigens
• RNA, Small Cytoplasmic
• RO60 protein, human
• Ribonucleoproteins
• Abatacept

Topics

• Abatacept (therapeutic use)
• Aged
• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (drug therapy, immunology)
• Autoantigens (immunology)
• Cohort Studies
• Female
• Humans
• Male
• Middle Aged
• RNA, Small Cytoplasmic (immunology)
• Ribonucleoproteins (immunology)